KN-92
Based on 11 publication(s) in Google Scholar
KN-92 is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a cell-permeable, reversible and competitive CaMKII inhibitor.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.91%
- No. CAS: 176708-42-2
- Fòrmula: C24H25ClN2O3S
- Peso molecular:456.98
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) KN-92
More- Nat Metab. 2020 Sep;2(9):918-933. [Abstract]
- Br J Anaesth. 2026 Jan 27:S0007-0912(25)00893-1. [Abstract]
- Curr Biol. 2026 May 4;36(9):2367-2381.e9. [Abstract]
- Brain Behav Immun. 2026 Mar 6:135:106529. [Abstract]
- Commun Biol. 2025 Mar 12;8(1):417. [Abstract]
- J Endocrinol. 2018 Mar;236(3):151-165. [Abstract]
- Sci Rep. 2023 Dec 7;13(1):21712. [Abstract]
- J Mol Cell Cardiol. 2022 Mar:164:110-125. [Abstract]
- Cell Calcium. 2021 Dec:100:102483. [Abstract]
- Proteomics. 2026 May;26(5):69-85. [Abstract]
- UCSF. 2025.
Actividad biológica
KN-93 (5-50 μM; 24 hours) inhibits LX-2 cell growth and KN-92 (5-50 μM; 24 hours) is ineffective in blocking cell growth[2].
The analysis of cell cycle regulator expression reveals that KN-93 rather than KN-92 reduces the expression of p53 and p21[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human hepatic stellate cells (LX-2)
-
Concentration:5-50 μM
-
Incubation Time:24 hours
-
Result:Ineffective in blocking cell growth.
Chemical Information
-
No. CAS 176708-42-2
-
Appearance Solid
-
Peso molecular 456.98
-
Fòrmula C24H25ClN2O3S
-
Color White to off-white
-
SMILES
O=S(C1=CC=C(OC)C=C1)(NC2=CC=CC=C2CN(C/C=C/C3=CC=C(Cl)C=C3)C)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Metab
AMPK controls the axonal regenerative ability of dorsal root ganglia sensory neurons after spinal cord injury. [Abstract]2020 Sep;2(9):918-933. PMID: 32778834 -
Br J Anaesth
Sevoflurane alters α5β3GABAA receptor trafficking via calcium/calmodulin-dependent protein kinase II-dependent β3 subunit phosphorylation to produce cognitive impairment in aged mice. [Abstract]2026 Jan 27:S0007-0912(25)00893-1. PMID: 41605734 -
Curr Biol
2026 May 4;36(9):2367-2381.e9. PMID: 42025171 -
Brain Behav Immun
NR2B-CaMKII signaling in the dentate gyrus driven by astrocytic P2Y1Rs mediates the antidepressant effect of low-dose LPS. [Abstract]2026 Mar 6:135:106529. PMID: 41796645 -
Commun Biol
Piezo1 promotes the progression of necrotizing enterocolitis by activating the Ca2(+)/CaMKII-dependent pathway. [Abstract]2025 Mar 12;8(1):417. PMID: 40074811 -
J Endocrinol
2018 Mar;236(3):151-165. PMID: 29371236 -
Sci Rep
Hippocampal CaMKII inhibition induces reactivation-dependent amnesia for extinction memory and causes fear relapse. [Abstract]2023 Dec 7;13(1):21712. PMID: 38066022 -
J Mol Cell Cardiol
Ventricular SK2 upregulation following angiotensin II challenge: Modulation by p21-activated kinase-1. [Abstract]2022 Mar:164:110-125. PMID: 34774547 -
Cell Calcium
Activation of transient receptor potential vanilloid 4 exacerbates myocardial ischemia-reperfusion injury via JNK-CaMKII phosphorylation pathway in isolated mice hearts. [Abstract]2021 Dec:100:102483. PMID: 34628110 -
Proteomics
Dynamic Phosphoproteomic Profiling Captured Early Signaling Events for Cold Acclimation in Larval Zebrafish. [Abstract]2026 May;26(5):69-85. PMID: 41906457 -
Solvente y solubilidad
DMSO : 100 mg/mL (218.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.47 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Smyth JT, et al. Inhibition of the inositol trisphosphate receptor of mouse eggs and A7r5 cells by KN-93 via a mechanism unrelated to Ca2+/calmodulin-dependent protein kinase II antagonism. J Biol Chem. 2002;277(38):35061-35070. [Content Brief]
[2]. An P, et al. KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007;13(9):1445-1448. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1883 mL | 10.9414 mL | 21.8828 mL | 54.7070 mL |
| 5 mM | 0.4377 mL | 2.1883 mL | 4.3766 mL | 10.9414 mL | |
| 10 mM | 0.2188 mL | 1.0941 mL | 2.1883 mL | 5.4707 mL | |
| 15 mM | 0.1459 mL | 0.7294 mL | 1.4589 mL | 3.6471 mL | |
| 20 mM | 0.1094 mL | 0.5471 mL | 1.0941 mL | 2.7353 mL | |
| 25 mM | 0.0875 mL | 0.4377 mL | 0.8753 mL | 2.1883 mL | |
| 30 mM | 0.0729 mL | 0.3647 mL | 0.7294 mL | 1.8236 mL | |
| 40 mM | 0.0547 mL | 0.2735 mL | 0.5471 mL | 1.3677 mL | |
| 50 mM | 0.0438 mL | 0.2188 mL | 0.4377 mL | 1.0941 mL | |
| 60 mM | 0.0365 mL | 0.1824 mL | 0.3647 mL | 0.9118 mL | |
| 80 mM | 0.0274 mL | 0.1368 mL | 0.2735 mL | 0.6838 mL | |
| 100 mM | 0.0219 mL | 0.1094 mL | 0.2188 mL | 0.5471 mL |
KN-92 Related Classifications
HY-15517 Related Classifications
Powered by Bioz